Tags

Type your tag names separated by a space and hit enter

The serological response to the phenolic glycolipid of Mycobacterium leprae in Australian and Nepali leprosy patients.
Aust N Z J Med. 1987 Dec; 17(6):568-73.AN

Abstract

Antibodies to the species-specific phenolic glycolipid (PGL-1) of Mycobacterium leprae and a crude M. leprae sonicate were measured by ELISA in sera from newly diagnosed and treated leprosy patients from Sydney and Nepal. IgM anti-PGL-1 antibodies were present in 88-90% of untreated patients at the lepromatous pole of the clinical spectrum and 35-55% of those at the tuberculoid pole. In treated patients with either form of the disease, IgM anti-PGL-1 antibodies were within the normal range or minimally elevated. In contrast, high levels of IgG anti-PGL-1 antibodies were detected in both treated and untreated patients. Neither IgM nor IgG anti-PGL-1 antibodies were elevated in sera from Mantoux negative controls and only one out of 15 sera from patients with untreated tuberculosis contained significant amounts of antibody. Comparison of the data from the anti-PGL-1 assay with the antibody response to a crude M. leprae sonicate revealed that the latter assay yielded more variable results and discriminated less well between lepromatous and tuberculoid subjects and between untreated patients and those on therapy. Thus the IgM anti-PGL-1 response signifies the presence of active disease, particularly in multi-bacillary cases, and has the potential to be used not only to monitor the response of these patients to therapy, but also to detect subclinical leprosy in high-risk groups such as the relatives of patients with lepromatous disease.

Authors+Show Affiliations

Britton WJ
Clinical Immunology Research Centre, University of Sydney, NSW.
Garsia RJ
No affiliation info available
Basten A
No affiliation info available

MeSH

Antibodies, BacterialAntigens, BacterialAustraliaEnzyme-Linked Immunosorbent AssayGlycolipidsHumansLeprosyMycobacterium lepraeNepalSerologic Tests

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

3328975

Citation

Britton, W J., et al. "The Serological Response to the Phenolic Glycolipid of Mycobacterium Leprae in Australian and Nepali Leprosy Patients." Australian and New Zealand Journal of Medicine, vol. 17, no. 6, 1987, pp. 568-73.
Britton WJ, Garsia RJ, Basten A. The serological response to the phenolic glycolipid of Mycobacterium leprae in Australian and Nepali leprosy patients. Aust N Z J Med. 1987;17(6):568-73.
Britton, W. J., Garsia, R. J., & Basten, A. (1987). The serological response to the phenolic glycolipid of Mycobacterium leprae in Australian and Nepali leprosy patients. Australian and New Zealand Journal of Medicine, 17(6), 568-73.
Britton WJ, Garsia RJ, Basten A. The Serological Response to the Phenolic Glycolipid of Mycobacterium Leprae in Australian and Nepali Leprosy Patients. Aust N Z J Med. 1987;17(6):568-73. PubMed PMID: 3328975.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The serological response to the phenolic glycolipid of Mycobacterium leprae in Australian and Nepali leprosy patients. AU - Britton,W J, AU - Garsia,R J, AU - Basten,A, PY - 1987/12/1/pubmed PY - 1987/12/1/medline PY - 1987/12/1/entrez SP - 568 EP - 73 JF - Australian and New Zealand journal of medicine JO - Aust N Z J Med VL - 17 IS - 6 N2 - Antibodies to the species-specific phenolic glycolipid (PGL-1) of Mycobacterium leprae and a crude M. leprae sonicate were measured by ELISA in sera from newly diagnosed and treated leprosy patients from Sydney and Nepal. IgM anti-PGL-1 antibodies were present in 88-90% of untreated patients at the lepromatous pole of the clinical spectrum and 35-55% of those at the tuberculoid pole. In treated patients with either form of the disease, IgM anti-PGL-1 antibodies were within the normal range or minimally elevated. In contrast, high levels of IgG anti-PGL-1 antibodies were detected in both treated and untreated patients. Neither IgM nor IgG anti-PGL-1 antibodies were elevated in sera from Mantoux negative controls and only one out of 15 sera from patients with untreated tuberculosis contained significant amounts of antibody. Comparison of the data from the anti-PGL-1 assay with the antibody response to a crude M. leprae sonicate revealed that the latter assay yielded more variable results and discriminated less well between lepromatous and tuberculoid subjects and between untreated patients and those on therapy. Thus the IgM anti-PGL-1 response signifies the presence of active disease, particularly in multi-bacillary cases, and has the potential to be used not only to monitor the response of these patients to therapy, but also to detect subclinical leprosy in high-risk groups such as the relatives of patients with lepromatous disease. SN - 0004-8291 UR - https://www.unboundmedicine.com/medline/citation/3328975/The_serological_response_to_the_phenolic_glycolipid_of_Mycobacterium_leprae_in_Australian_and_Nepali_leprosy_patients_ DB - PRIME DP - Unbound Medicine ER -